Terguride--a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine. 著者: Ciccarelli, E, Touzel, R, Besser, M, Grossman, A

The growth hormone secretagogue receptor. 著者: Korbonits, M, Ciccarelli, E, Ghigo, E, Grossman, AB

Long-term treatment with a new repeatable injectable form of bromocriptine, Parlodel LAR, in patients with tumorous hyperprolactinemia. 著者: Ciccarelli, E, Miola, C, Avataneo, T, Camanni, F, Besser, G, Grossman, A

Subcutaneous growth hormone-releasing hormone augments pulsatile nocturnal GH release in GH-insufficient children, but may also raise basal GH secretion. 著者: Ross, R, Kirk, J, Tsagarakis, S, Trainer, P, Ciccarelli, E, Touzel, R, Grossman, A, Savage, M, Besser, G

Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. 著者: Hubina, E, Nanzer, A, Hanson, MR, Ciccarelli, E, Losa, M, Gaia, D, Papotti, M, Terreni, MR, Khalaf, S, Jordan, S, Czirják, S, Hanzély, Z, Nagy, G, Góth, M, Grossman, AB, Korbonits, M

The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders an open, uncontrolled, multicentre study 著者: Ismail, I.S., Webster, J., Piscitelli, G., Polli, A., D'Alberton, A., Falsetti, L., Ferrari, C., Fioretti, P., Giordano, G., L'Hermite, M., Ciccarelli, E., Crosignani, P.G., DeCecco, L., Fadini, R., Faglia, G., Flamigni, C., Tamburrano, G., Scanlon, M.F.

全文の入手